Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

The asset is in a phase 1 trial both as a monotherapy and in combination with Merck & Co.’s PD-1 inhibitor Keytruda in patients with solid tumors resistant to immune checkpoint inhibitors. The biotech ...

Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer and eye-diseases, announced today that is has ...

Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes ...